PharmaNet Development Group Hosts Phase IV Symposium in London on June 3, 2010

PRINCETON, N.J., May 11 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of clinical development services to innovative pharmaceutical, biotechnology, generic drug and medical device companies, is pleased to announce that it is hosting a complimentary symposium entitled "Safety and Value: Critical Success Factors for Post-Approval Research" at the Royal College of Surgeons in London, United Kingdom on June 3, 2010.

Post-approval studies are essential in characterizing the real-world performance of medical products in terms of safety, effectiveness, economic value and quality of life. During this symposium, industry leaders will join PharmaNet experts to discuss techniques to optimize post-approval research including:

  • Strategic Post-Approval Research Planning, Jeff Trotter, Executive Vice President, Phase IV Development, PharmaNet

  • The Evolving Post-Approval Regulatory Environment in Europe, Franz Buchholzer, Vice President, Regulatory Operations, PharmaNet

  • Issues in Safety, Epidemiology, and Risk Management, Rav Seeruthun, Head of CNS and GI, Eisai Europe and George Seaton, Clinical Trials Manager, Eisai Europe

  • Obtaining Real-World Evidence through Observational Research and Patient Registries, Ron Weishaar, Executive Director, Observational Research, PharmaNet

  • Establishing Product Value through Health Economics and Outcomes Research (HEOR), Michael Nelson, Executive Director, Health Economics and Outcomes Research, PharmaNet

  • Post-Approval Case Studies, Ken Ashman, Executive Director, Phase IV European Operations, PharmaNet

Please contact Andrew Ecob at [email protected] or +1 44 1494 560 426 for more information or to attend the event. Space is limited.  

About PharmaNet Development Group, Inc.

PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,300 employees in 34 counties and 42 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical development. For more information, please visit our website at www.pharmanet.com.  

Contact:

Anne-Marie Hess

Phone:

609 951 6842

E-mail:

[email protected]



SOURCE PharmaNet Development Group, Inc.

Suggested Articles

Gilead Sciences is paying Nurix $45 million upfront in a deal that could reach $2.3 billion in value if all milestones are met and royalties realized.

In mice, Kymera's lead drug promoted tumor regression, both on its own and in combination with BTK inhibitor Imbruvica.

The report features testimony that some NHS bodies are “actively instructed not to deal with industry by their local leadership.”